IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

被引：0
|
作者：
Starodub, Alexander
Ocean, Allyson J.
Guarino, Michael J.
Picozzi, Vincent J.
Thomas, Salim Samuel
Messersmith, Wells A.
Shah, Manlsh A.
Vandat, Linda T.
Chuang, Ellen
Lin, Bruce S.
Govindan, Serengulam V.
Maliakal, Pius P.
Wegener, William A.
Hamburger, Steven A.
Sharkey, Robert M.
Goldenberg, David M.
机构：
[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Univ Florida, Hlth Canc Ctr, Orlando Hlth, Orlando, FL USA
[6] Univ Colorado Denver, Div Med Oncol, Aurora, CO USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Immunomedics Inc, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.3032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3032
引用
收藏
页数：1
相关论文
共 44 条
  • [1] SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Vahdat, Linda T.
    Chuang, Ellen
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
  • [3] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
    Sharkey, Robert M.
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Guarino, Michael
    Messersmith, Wells A.
    Berlin, Jordan D.
    Picozzi, Vincent J.
    Moroose, Rebecca
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [4] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
    Camidge, D. R.
    Starodub, Aleander N.
    Ocean, Allyson
    Messersmith, Wells A.
    Bardia, Aditya
    Thomas, Sajeve S.
    Masters, Gregory
    Heist, Rebecca
    Maliakal, Pius
    Govindan, Serengulam
    Sharkey, Robert M.
    Wilhelm, Francois E.
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
  • [5] Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
    Goldenberg, David M.
    Rossi, Edmund A.
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    McBride, William J.
    Zalath, Maria
    Terracina, Gaby
    Trisal, Preeti
    Sharkey, Robert M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Trisal, Preeti
    Arrojo, Roberto
    Liu, Donglin
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    BIOCONJUGATE CHEMISTRY, 2015, 26 (05) : 919 - 931
  • [7] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Vahdat, Linda T.
    Isakoff, Steven J.
    Guarino, Michael
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Mayer, Ingrid A.
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER, 2017, 123 (19) : 3843 - 3854
  • [8] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [9] Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Bardia, Aditya
    Guarino, Michael J.
    Messersmith, Wells
    Berlin, Jordan
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Masters, Gregory
    Vandat, Linda T.
    Mayer, Ingrid A.
    Moroose, Rebecca
    Diamond, Jennifer S.
    Tagawa, Scott T.
    Shah, Manish A.
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2015, 75
  • [10] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
    Camidge, D. Ross
    Heist, Rebecca Suk
    Masters, Gregory A.
    Scheff, Ronald J.
    Starodub, Alexander
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Horn, Leora
    Berlin, Jordan
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345